Stock Ratings / Health Care / ICU / dividends

FEMY (30) PLSM (47) SINT (33) CNSY (25) ⌘ Pro Terminal →

SeaStar Medical Holding Corporation (ICU) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.24 -3.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.22

SeaStar Medical Holding Corporation (ICU) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $11.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ICU Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ICU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, SeaStar Medical Holding Corporation (NASDAQ: ICU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.24 (-3.03% 1D, market cap $11.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ICU ranks #776 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ICU compare to FEMY and PLSM in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), ICU carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 95.7%, and ROIC of -35.0%. By comparison, FEMY (Femasys Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $11.5M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, ICU leads on earnings multiple (N/A) while ICU leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ICU?

▼

Per ICU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831868), SeaStar Medical Holding Corporation generated $1.2M in revenue (+814.1% YoY), -$12.2M in net income, and -$13.6M in free cash flow against $14.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.22 (-0.74%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICU)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY ICU SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (35% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 36.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.59-15% Next Q

Q2 (-2Q)

Grade E$3.05-17.4% Next Q

Q3 (-1Q)

Grade E$2.52-11.1% Next Q

Current

Grade E$2.24-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ICU Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ICU currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.16) and Max Pain ($2.35) forces dealer call-delta covering toward $6.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICU• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ICU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.7K

Yr 3

$18.3K

Yr 4

$21.3K

Yr 5

$24.7K

Yr 6

$28.8K

Yr 7

$33.5K

Yr 8

$38.9K

Yr 9

$45.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICU)

✓Walkthrough of ICU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ICU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.27%🛡️ HOLDING TREND SUPPORT

2026-11-03O $2.31H $2.31L $2.24C $2.24VOL 81.7K

RES: $5.36SUP: $2.11SMA50: $3.16SMA200: $3.32

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ICU Butterfly Map → + Track ICU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ICU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ICU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICU)

Health Care Rank #776 of 1016 ⚔️ FEMY vs ICU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICU vs. FEMY, PLSM, SINT, CNSY)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SeaStar Medical Holding Corporation (ICU) ranks #776 by composite RQD confidence (31/100, grade E) and #879 by equity capitalization ($11.8M). Within this direct 5-issuer industry benchmark cohort, ICU leads on earnings valuation at N/A trailing P/E, while ICU leads on capital efficiency and profitability with -35.0% ROIC and 95.7% gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ICU at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ICU ACTIVE SeaStar Medical Holding Corporation	E	31/100	—	95.7%	-35.0%	-3.03%	$11.8M	Benchmark Subject
FEMY Femasys Inc.	E	30/100	—	62.0%	-35.0%	+1.11%	$11.5M	/femy-vs-icu →
PLSM Pulsenmore Ltd.	D	47/100	—	—	—	+3.09%	$10.9M	/plsm-vs-icu →
SINT SiNtx Technologies Inc.	E	33/100	—	45.3%	-35.0%	-1.16%	$12.8M	/sint-vs-icu →
CNSY Cerenome Inc.	E	25/100	—	—	-35.0%	-2.30%	$12.9M	/cnsy-vs-icu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001831868

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SeaStar Medical Holding Corporation (ICU) reported GAAP revenue of $1.2M (+814.1% vs. FY2024 revenue of $135.0K ) , GAAP net income of -$12.2M, operating cash flow of -$13.6M, and free cash flow of -$13.6M (+15.0% YoY). On the balance sheet, ICU closed FY2025 with $14.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.2M	-$12.2M	-$13.6M	-$13.6M	$14.2M	—
FY2024 (FY)	2024-12-31	$135.0K	-$24.8M	-$16.0M	-$16.0M	$4.7M	—
FY2023 (FY)	2023-12-31	$0	-$26.2M	-$10.3M	-$10.3M	—	—

3. ICU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ICU compare to FEMY and PLSM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ICU?

Where is ICU trading relative to its 50-day, 200-day, and 52-week technical levels?

ICU last traded at $2.24 (-3.03% on volume of 81,711 shares), positioning the stock -29.11% below its 50-day simple moving average ($3.16) and -32.53% below its 200-day simple moving average ($3.32). Across its 52-week range of $2.07 to $6.00, ICU sits at the 4.3% percentile with a 14-day RSI of 36.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.96 to $2.52).

ICU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ICU pay a dividend and is it safe?

SeaStar Medical Holding Corporation (ICU) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ICU RQD Cockpit ICU 12M Forecast ICU Earnings & Move ICU Dividends & DRIP ICU Insiders & 13F ICU Whale Options ICU Profit Sankey ICU News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ICU — SeaStar Medical Holding Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:18Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, the stock scores 31 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 4 out of 20, reflecting ROIC of -35% and an FCF yield of 0%, which indicates the business is not currently generating returns on capital or free cash flow. The Whale 13F Flow pillar scores 3 out of 20 for institutional accumulation and options positioning, a weak reading on sponsorship. The Insider Conviction pillar scores 5 out of 20 based on SEC Form 4 and Congressional PTR cluster flow, signaling limited insider support. The Macro Regime Fit pillar scores 8 out of 20 with a Beta of 1.0 and sector sensitivity noted. The Forensic Balance Sheet pillar scores 11 out of 20, citing an Altman Z-Score of 2.5, a Piotroski F-Score of 4/9, and a Debt/Equity ratio of 0.5. For a prospective investor, the rating frames the stock as a high-risk, low-support profile: the fundamental engine is the weakest pillar, insider and institutional signals are thin, and the forensic picture is mixed rather than distressed. Any upside case would need to rest on a turnaround in cash generation that the reported financials do not yet show.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1.2M	$-12.2M	$-12.2M	N/A	$-13.6M	N/A	N/A
FY 2024	$0.1M	$-17.8M	$-24.8M	N/A	$-16.0M	N/A	N/A
FY 2023	$0.0M	$-14.2M	$-26.2M	N/A	$-10.3M	N/A	N/A

Per the SEC financials, the company has reported operating losses in each of the three periods shown, with net income negative throughout. Per the market data, operating margin is -60% and net margin is -60%, with ROIC at -35%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 4/9, and a Debt/Equity ratio of 0.5 as forensic inputs. Cash and debt balances are not reported in the source data.

Open Questions

What products does the company sell, and who are its customers, given the sparse business description in the source data?
What are the company's cash and debt balances, which are reported as N/A in the financial data?
What drove the revenue increase from $0.0M in FY 2023 to $1.2M in FY 2025, and is it recurring?
What is the company's path to positive operating income, given losses in every reported period?
What institutional or insider ownership exists, since the holders and analyst sections are empty?

ICU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SeaStar Medical Holding Corporation (ICU) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ICU Debate Forum (3) ↓

🟡 MARKET WIRE Benzinga • 3d ago

SeaStar Medical Files Prospectus For Offering 1.768M Common Shares On Behalf Of Selling Shareholders

https://www.sec.gov/Archives/edgar/data/1831868/000121390026114387/ea0309845-s3_seastar.htm

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 10d ago

ICU: QUELIMMUNE® Demonstrates Statistically Significant Survival Benefit in SAVE Registry Patients

By David Bautz, PhD NASDAQ: ICU READ THE FULL ICU RESEARCH REPORT Business Update Statistically Significant Survival Benefit Shown for QUELIMMUNE® On October 22, 2026, SeaStar Medical Holding Corp. (ICU) announced the pr

Read Full Source ↗

🟢 CATALYST Yahoo • 11d ago

SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI

New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discha

Read Full Source ↗

🔴 RISK WATCH Benzinga • 11d ago

SeaStar Medical Reports 65.1% Survival Rate At Day 90 In Its QUELIMMUNE SAVE Registry Analysis Presented At ASN Kidney Week 2026

SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 19d ago

These stocks have an unusual volume in today's session

Volume analysis on 2026-10-14: stocks with an unusual volume in today's session.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 19d ago

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

Award recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support Keynote presentation and award cerem

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ICU Bull vs. Bear Conversation Board — What's Your Call at $2.24?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ICU 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.03 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ICU (E • RQD 31/100) a Buy at $2.31?

Welcome to the ICU (SeaStar Medical Holding Corporation) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.80 (-22.1%)

Spot @ $2.31

Pump the brakes on ICU — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ICU, but look at what you are paying: current EV/EBITDA multiples with 95.7% gross margins. Unless SeaStar Medical Holding Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.89 (+25.1%)

Spot @ $2.31

ICU cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ICU, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $2.31 (52-wk range $2.07 - $6.00), any beat on forward guidance forces shorts and underweight funds to chase.